Dachaigh › Arthritis Psoriatic › Georgia
Sgrùdaidhean clionaigeach Arthritis Psoriatic ann an Georgia
Tha 7 sgrùdaidhean airson Arthritis Psoriatic a’ lorg phàirtichean aig làraichean ann an Georgia.
Teacsa sgrùdaidh oifigeil (Beurla)
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
- Atlanta Research Center for Rheumatology, Marietta
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07321873A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Emory University, Atlanta
- Children's Center for Digestive Healthcare, Atlanta
A’ fastadhÌre 3
Aoisean 3 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06663332A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- Marietta Rheumatology Associates, Marietta
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT06671483Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
- Clinical Site, Gainesville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT06641089A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
- North Georgia Rheumatology Group PC, Lawrenceville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06671496Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
- Emory Children's Center, Atlanta
- Georgia Regents University Medical Center, Augusta
A’ fastadhSgrùdadh amharc
Suas gu aois 21 · Gach gnè · Air ùrachadh 27 Lùna 2026 · NCT02418442Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
- Parris and Associates, Lilburn
A’ fastadhÌre 3
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 9 Dàmh 2025 · NCT05669833Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.